These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction. Mills KH Immunol Lett; 2009 Feb; 122(2):108-11. PubMed ID: 19100777 [TBL] [Abstract][Full Text] [Related]
4. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Klinman DM; Klaschik S; Sato T; Tross D Adv Drug Deliv Rev; 2009 Mar; 61(3):248-55. PubMed ID: 19272313 [TBL] [Abstract][Full Text] [Related]
5. New adjuvants for human vaccines. Mbow ML; De Gregorio E; Valiante NM; Rappuoli R Curr Opin Immunol; 2010 Jun; 22(3):411-6. PubMed ID: 20466528 [TBL] [Abstract][Full Text] [Related]
6. Type I interferons as vaccine adjuvants against infectious diseases and cancer. Bracci L; La Sorsa V; Belardelli F; Proietti E Expert Rev Vaccines; 2008 Apr; 7(3):373-81. PubMed ID: 18393607 [TBL] [Abstract][Full Text] [Related]
8. Technologies for enhanced efficacy of DNA vaccines. Saade F; Petrovsky N Expert Rev Vaccines; 2012 Feb; 11(2):189-209. PubMed ID: 22309668 [TBL] [Abstract][Full Text] [Related]
9. Letter from the editor. Ellis R; Riedmann EM Hum Vaccin Immunother; 2014; 10(4):813-4. PubMed ID: 24784356 [No Abstract] [Full Text] [Related]
10. The impact of vaccines and vaccinations: Challenges and opportunities for modelers. Curtiss R Math Biosci Eng; 2011 Jan; 8(1):77-93. PubMed ID: 21361401 [TBL] [Abstract][Full Text] [Related]